Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTHI19T)

• DTT Name: Staphylococcus Beta-lactamase (Stap-coc blaZ)
• Synonyms: blaZ; Cephalosporinase
• Gene Name: Stap-coc blaZ
• DTT Type: Successful target; [1]
• Related Disease:
  Bacterial infection [ICD-11: 1A00-1C4Z]
  Infectious gastroenteritis/colitis [ICD-11: 1A40]
  Urinary tract infection [ICD-11: GC08]
• BioChemical Class: Carbon-nitrogen hydrolase
• UniProt ID: BLAC_STAAU
• TTD ID: T38179
• EC Number: EC 3.5.2.6
• Sequence:
  MKKLIFLIVIALVLSACNSNSSHAKELNDLEKKYNAHIGVYALDTKSGKEVKFNSDKRFA
  YASTSKAINSAILLEQVPYNKLNKKVHINKDDIVAYSPILEKYVGKDITLKALIEASMTY
  SDNTANNKIIKEIGGIKKVKQRLKELGDKVTNPVRYEIELNYYSPKSKKDTSTPAAFGKT
  LNKLIANGKLSKENKKFLLDLMLNNKSGDTLIKDGVPKDYKVADKSGQAITYASRNDVAF
  VYPKGQSEPIVLVIFTNKDNKSDKPNDKLISETAKSVMKEF
• Function: This protein is a serine beta-lactamase with a substrate specificity for cephalosporins.

Molecular Interaction Atlas (MIA) of This DTT

4 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ceftolozane/tazobactam	DM9QWAH	Discovery agent	N.A.	Approved	[2]
Clavulanate	DM2FGRT	Bacterial infection	1A00-1C4Z	Approved	[3]
Meropenem + vaborbactam	DMOVAIX	Intra-abdominal infection	1A40	Approved	[4]
Tazobactam	DM3XNUI	Bacterial infection	1A00-1C4Z	Approved	[1]

9 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CAZ AVI	DMPG4OM	Serious infection	1H0Z	Phase 3	[5]
Enmetazobactam	DMZKTYJ	Urinary tract infection	GC08	Phase 3	[6]
Vaborbactam	DMDCFXJ	Urinary tract infection	GC08	Phase 3	[7]
CXL	DM3JFZ2	Methicillin-resistant staphylococci infection	1A00-1A09	Phase 2	[8]
MK-7655	DMLMV0O	Bacterial infection	1A00-1C4Z	Phase 2	[9]
ME-1071	DMEMQ5J	Bacterial infection	1A00-1C4Z	Phase 1	[10]
OP-0595	DMECVP9	Bacterial infection	1A00-1C4Z	Phase 1	[11]
RASV-Sp	DM4VTX6	Streptococcus infection	1B53	Phase 1	[12]
VNRX-5133	DMNZ6XH	Bacterial infection	1A00-1C4Z	Phase 1	[13]

9 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
2085-P	DM0GMJ6	Otitis media	AA80-AB0Z	Discontinued in Phase 3	[14]
DA-7101	DMHSLVO	Gram-positive bacterial infection	1B74-1G40	Discontinued in Phase 3	[15]
P1A	DMWCAQD	Toxicity	N.A.	Discontinued in Phase 2	[16]
BRL-42715	DMBC12X	Bacterial infection	1A00-1C4Z	Terminated	[17]
CL-186659	DMYML2N	Bacterial infection	1A00-1C4Z	Terminated	[14]
Ro-48-1220	DMXMP3D	Bacterial infection	1A00-1C4Z	Terminated	[18]
Ro-48-5545	DM7AUF2	Bacterial infection	1A00-1C4Z	Terminated	[19]
Ro-48-8724	DM0RZEO	Multidrug resistant infection	MG51	Terminated	[20]
SB-236049	DM5JDH1	Bacterial infection	1A00-1C4Z	Terminated	[21]

44 Investigative Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
(P-Iodophenylacetylamino)Methylphosphinic Acid	DMB8NWI	Discovery agent	N.A.	Investigative	[22]
1-Aminopropane-1,2,3-tricarboxylic acid	DMPYCK5	Discovery agent	N.A.	Investigative	[23]
2-(N-Morpholino)-Ethanesulfonic Acid	DMZVHSB	Discovery agent	N.A.	Investigative	[22]
2-(Sulfanylmethyl)phenylphosphonic acid	DM5CEG8	Discovery agent	N.A.	Investigative	[24]
2-mercaptophenylphosphonic acid	DM8HSBT	Discovery agent	N.A.	Investigative	[24]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[22]
2-phenyl-1H-imidazole-4-carboxylic acid	DMZI7O1	Discovery agent	N.A.	Investigative	[25]
3-Amino-3-(methoxycarbonyl)-1,5-pentandioic acid	DMV4XGT	Discovery agent	N.A.	Investigative	[23]
3-ethoxycarbonylpyroglutamate	DM4YL5Q	Discovery agent	N.A.	Investigative	[23]
3-Nitrophenylboronic Acid	DMPMX8R	Discovery agent	N.A.	Investigative	[22]
4,4'-Biphenyldiboronic Acid	DMFGQ02	Discovery agent	N.A.	Investigative	[22]
4-(Carboxyvin-2-Yl)Phenylboronic Acid	DMSG9LV	Discovery agent	N.A.	Investigative	[22]
4-Carboxyphenylboronic Acid	DM8A2QO	Discovery agent	N.A.	Investigative	[22]
4-iodo-acetamido phenylboronic acid	DMFSH2I	Discovery agent	N.A.	Investigative	[22]
4-Methyl-3-(2-oxo-azetidin-1-yl)-benzoic acid	DMH6QZO	Discovery agent	N.A.	Investigative	[26]
4-[(METHYLSULFONYL)AMINO]BENZOIC ACID	DMXKT6M	Discovery agent	N.A.	Investigative	[25]
5-Fluoro-2-sulfanyl-phenylphosphonic acid	DMUCLAV	Discovery agent	N.A.	Investigative	[24]
5-hydroxymethylbenzo[b]thiophen-2-ylboronic acid	DMN9FPV	Discovery agent	N.A.	Investigative	[27]
5-methyl-benzo[b]thiophen-2-ylboronic acid	DMLJVB7	Discovery agent	N.A.	Investigative	[27]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[22]
Acylated Ceftazidime	DMIZ5VO	Discovery agent	N.A.	Investigative	[22]
Alpha-Sulfanyl(2,4-dichlorobenzyl)phosphonic acid	DMWL172	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanyl(2-methoxybenzyl)phosphonic acid	DM42M6I	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanyl(4-bromobenzyl)phosphonic acid	DMRIWDV	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanyl(4-chlorobenzyl)phosphonic acid	DMP6GXU	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanyl(4-fluorobenzyl)phosphonic acid	DMP9V42	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanylbenzylphosphonic acid	DMWB07I	Discovery agent	N.A.	Investigative	[24]
Alpha-Sulfanylpropylphosphonic acid	DM19NAI	Discovery agent	N.A.	Investigative	[24]
Benzo[b]thiophen-2-ylboronic acid	DMJQSLW	Discovery agent	N.A.	Investigative	[22], [27]
Carbamic Acid	DMJQ3LN	Discovery agent	N.A.	Investigative	[22]
Clavulanate+Amoxicillin	DMAJNYM	Infectious disease	1A00-CA43.1	Investigative	[28]
Degraded Cephaloridine	DMKRT20	Discovery agent	N.A.	Investigative	[22]
Diisopropyl 1-mercaptopropylphosphonate	DMNR439	Discovery agent	N.A.	Investigative	[24]
Diisopropyl 2-(sulfanylmethyl)phenylphosphonate	DMVFJAH	Discovery agent	N.A.	Investigative	[24]
Diisopropyl mercapto(phenyl)methylphosphonate	DMHKE3M	Discovery agent	N.A.	Investigative	[24]
Hydrolyzed Cephalothin	DMWH92F	Discovery agent	N.A.	Investigative	[22]
M-Aminophenylboronic Acid	DM213MD	Discovery agent	N.A.	Investigative	[22]
N-2-Thiophen-2-Yl-Acetamide Boronic Acid	DMLK0J8	Discovery agent	N.A.	Investigative	[22]
PCNOTAXIME GROUP	DMGS6YH	Discovery agent	N.A.	Investigative	[25]
Sucrose	DMVWUCF	Discovery agent	N.A.	Investigative	[29]
Thiophene-2-ylboronic acid	DML3OHW	Discovery agent	N.A.	Investigative	[27]
Tribenzyl 2-aminopropane-1,2,3-tricarboxylate	DMYSX0K	Discovery agent	N.A.	Investigative	[23]
Triethyl 2-aminopropane-1,2,3-tricarboxylate	DM5Q7K8	Discovery agent	N.A.	Investigative	[23]
[[N-(Benzyloxycarbonyl)Amino]Methyl]Phosphate	DM86305	Discovery agent	N.A.	Investigative	[22]

References

• [1] Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
• [2] 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
• [3] A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
• [4] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [5] NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
• [6] Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
• [7] Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
• [8] Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
• [9] Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
• [10] Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
• [11] OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.
• [12] WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
• [13] Discovery of Taniborbactam (VNRX-5133): A Broad-Spectrum Serine- and Metallo--lactamase Inhibitor for Carbapenem-Resistant Bacterial Infections. J Med Chem. 2020 Mar 26;63(6):2789-2801.
• [14] US patent application no. 2004,0023,290, Novel therapeutic agents that modulate enzymatic processes.
• [15] Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
• [16] IPSAT P1A, a class A beta-lactamase therapy for the prevention of penicillin-induced disruption to the intestinal microflora. Curr Opin Investig Drugs. 2009 Aug;10(8):838-44.
• [17] In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor. Antimicrob Agents Chemother. 1989 Sep;33(9):1580-7.
• [18] Comparative in vitro activity of apalcillin alone and combined with Ro 48-1220, a novel penam beta-lactamase inhibitor. Clin Microbiol Infect. 1995 Feb;1(2):86-100.
• [19] Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases. J Antimicrob Chemother. 1997 Sep;40(3):335-43.
• [20] Activity of a broad-spectrum cephalosporin (Ro 48-8391) alone and in combination with two novel beta-lactamase inhibitors (Ro 48-5545 and Ro 48-8724). Diagn Microbiol Infect Dis. 1998 Oct;32(2):85-94.
• [21] Identification of a series of tricyclic natural products as potent broad-spectrum inhibitors of metallo-beta-lactamases. Antimicrob Agents Chemother. 2002 Jun;46(6):1880-6.
• [22] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [23] Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D beta-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3593-7.
• [24] Mercaptophosphonate compounds as broad-spectrum inhibitors of the metallo-beta-lactamases. J Med Chem. 2010 Jul 8;53(13):4862-76.
• [25] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [26] N-aryl 3-halogenated azetidin-2-ones and benzocarbacephems, inhibitors of beta-lactamases. J Med Chem. 1988 Feb;31(2):370-4.
• [27] Optimizing cell permeation of an antibiotic resistance inhibitor for improved efficacy. J Med Chem. 2007 Nov 15;50(23):5644-54.
• [28] Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64.
• [29] Ten S, Maclaren N: Insulin resistance syndrome in children. J Clin Endocrinol Metab. 2004 Jun;89(6):2526-39.